Dayvigo Regret, Stopping, and Restarting: Real Patient Experiences and Clinical Guidance

Is Dayvigo a controlled substance?

Yes. The Dayvigo label states that the product contains lemborexant, a Schedule IV controlled substance [1]. FDA approved Dayvigo on December 20, 2019 [3], and DEA placed lemborexant in Schedule IV by an interim final rule effective April 7, 2020 [4][5]. On August 11, 2026, DEA published a proposed rule to move suvorexant, lemborexant and daridorexant from Schedule IV to Schedule V; comments closed September 10, 2026, and no final rule had been published as of October 29, 2026, so lemborexant is still Schedule IV [2].

The label treats abuse and physical dependence separately. In a human abuse potential study in 29 recreational sedative users, lemborexant 10, 20 and 30 mg produced drug-liking responses statistically similar to zolpidem 30 mg and suvorexant 40 mg, and greater than placebo [1].

Does stopping lemborexant cause withdrawal?

The label's dependence section says it did not in the studies run. In animal studies and clinical trials, chronic administration of lemborexant did not produce withdrawal signs or symptoms when the drug was stopped, which the label says suggests lemborexant does not produce physical dependence [1].

That is not the same as saying nothing happens after the last tablet. Dayvigo's effects on alertness may persist in some people for up to several days after stopping [1].

What the trials recorded about adverse reactions and discontinuation

The label reports discontinuation for adverse reactions in the first 30 days at 2.6% for 10 mg and 1.4% for 5 mg, versus 1.5% on placebo; across the 6-month placebo-controlled period the figures were 8.3%, 4.1% and 3.8% [1].

Somnolence is the labelled common reaction: 10% at 10 mg, 7% at 5 mg and 1% on placebo in the first 30 days [1]. Nightmare or abnormal dreams were reported by 2.2% at 10 mg, 0.9% at 5 mg and 0.9% on placebo [1].

What the phase 3 trials actually showed

SUNRISE 1 was a 1-month randomized, double-blind trial in 1,006 adults aged 55 and older with insomnia disorder, comparing placebo (n=208), zolpidem extended-release 6.25 mg (n=263), lemborexant 5 mg (n=266) and lemborexant 10 mg (n=269). The primary endpoint was change from baseline in latency to persistent sleep on polysomnography versus placebo; the ratio versus placebo was 0.77 at 5 mg and 0.72 at 10 mg (both P<.001) [6].

SUNRISE 2 randomized 949 adults aged 18 and older and reported on a 6-month placebo-controlled period within a 12-month trial. Subjective sleep onset latency, subjective wake after sleep onset and subjective sleep efficiency all improved significantly versus placebo at month 6 and at most time points, and most adverse events were mild or moderate [7].

Restarting after a gap

There is no separate labeled dose for restarting Dayvigo. The recommended dose is 5 mg once nightly, taken immediately before bed with at least 7 hours remaining before the planned time of awakening, and it may be increased to a maximum of 10 mg based on clinical response and tolerability [1]. Time to sleep onset may be delayed if the drug is taken with or soon after a meal [1].

Two pharmacokinetic facts from the label bear on timing. The effective half-life is about 17 hours at 5 mg and 19 hours at 10 mg. After a high-fat meal, peak concentration fell 23% and time to peak was delayed two hours [1].

Drug interactions that change the dose

Lemborexant is metabolized mainly by CYP3A4, and the label handles interactions by changing or ruling out the dose [1]. The Dayvigo label says to avoid combining it with strong CYP3A inhibitors such as itraconazole and clarithromycin, or moderate ones such as fluconazole and verapamil. With weak inhibitors such as chlorzoxazone and ranitidine, the labeled maximum is 5 mg [1]. The label says to avoid combining it with strong or moderate CYP3A inducers such as rifampin, carbamazepine, St. John's wort, bosentan, efavirenz, etravirine and modafinil, which decrease lemborexant exposure and may reduce its efficacy [1].

In the other direction, lemborexant decreases the AUC of CYP2B6 substrates such as bupropion and methadone, which may reduce their efficacy; the label advises monitoring the response to those drugs and considering dose increases [1]. Alcohol raises lemborexant peak and total exposure and produced a numerically greater negative effect on postural stability and memory than alcohol alone when assessed near the 2-hour peak; the label says to avoid alcohol with Dayvigo [1]. The label also states that using Dayvigo with other insomnia drugs is not recommended [1].

Safety items in the label's Warnings and Precautions

Sleep paralysis was reported in 1.6% of patients on 10 mg and 1.3% on 5 mg, versus no reports on placebo; hypnagogic hallucinations in 0.7% and 0.1%, again versus none on placebo [1]. Complex sleep behaviors such as sleep-walking, sleep-driving, eating or making phone calls have been reported with hypnotics such as Dayvigo, and the label says to discontinue immediately if one occurs; two such events occurred in the trials, both at 10 mg [1]. Dayvigo carries no boxed warning, and complex sleep behaviors sit in Warnings and Precautions [3][1].

Suicidal ideation or behavior assessed by questionnaire occurred in 0.3% on 10 mg and 0.4% on 5 mg versus 0.2% on placebo, and the label notes that worsening depression is possible and that the lowest feasible number of tablets should be prescribed [1]. Because the drug can cause drowsiness, the label says patients, particularly the elderly, are at higher risk of falls [1]. Driving ability was impaired in some subjects taking 10 mg, and the label cautions patients on that dose against next-day driving [1]. Respiratory effects were studied in mild to severe obstructive sleep apnea and moderate to severe COPD in short-term trials, and the label says the effect on respiratory function should be considered in patients with compromised breathing [1].

Liver impairment and contraindication

Moderate hepatic impairment caps the dose at 5 mg once nightly, and the drug is not recommended in severe hepatic impairment [1]. The only labeled contraindication is narcolepsy [1].